Introduction: Muscle wasting has detrimental effects, including increased mortality. Identifying patients at risk can guide treatment efforts.
Results: In all, 53% of patients had loss of lean body mass and 49% had loss of stair climb power (SCP) at day 84 of treatment. Of the 322 patients who received placebo, 232 with observable outcome and baseline covariates were included for lean body mass analysis and 236 for SCP analysis. More advanced disease predicted a higher probability of greater physical loss (OR ¼ 1.96; 95% confidence interval [CI]: 1.14-3.36). Three factors predicted higher probability of SCP loss: taxane chemotherapy (OR ¼ 1.73; 95% CI: 1.06-2.83), tobacco use before chemotherapy (OR ¼ 2.15, 95% CI: 1. 10-4.18) , and SCP at baseline (OR ¼ 1.01, 95% CI: 1.004-1.015). Higher body mass index was a protective factor for functional loss (OR ¼ 0.85; 95% CI: 0.73-0.98). A higher Eastern Cooperative Oncology Group Performance Status trended toward being predictive of greater probability of both physical loss (0.767) and functional loss (0.070), but the results were not statistically significant.
Conclusions:
Approximately 50% of patients with advanced lung cancer who were undergoing chemotherapy had ongoing loss of muscle mass and muscle function.
Advanced stage predicted physical loss. Tobacco use and taxane chemotherapy predicted functional loss. Body mass index was a protective factor for functional loss. We identified predictors of physical and functional loss that could be used as therapeutic targets or to guide treatment efforts.
Introduction
In recent years the definition of cachexia changed to include a deficiency of skeletal muscle mass, or sarcopenia, as a key feature. On the basis of the 2011 international consensus, patients meet the criteria for cancer cachexia by unintentionally losing more than 5% of their body weight in 6 months or by unintentionally losing more than 2% of their body weight if they have either a body mass index (BMI) lower than 20 or sarcopenia. 1 Muscle depletion is prevalent in patients with cancer; it is present in 60% to 80% of those with advanced cancer. 2 Even in obese patients, depletion of skeletal muscle is an independent predictor of survival. 3, 4 The inclusion of sarcopenia in the definition of cancer cachexia highlights the importance of body composition over body mass.
Patients with depletion of muscle mass have a higher rate of infections, 5 longer hospitalizations, 6 and more postoperative complications. 6, 7 In patients with cancer, the presence of sarcopenia decreases the time to tumor progression 8 and increases chemotherapy's toxicity. 8, 9 Sarcopenia, more than BMI, is a strong risk factor for mortality in cancer. 3 Low skeletal muscle index is independently associated with shorter survival in patients with cancer, even when low body weight is not. 10 Patients with low muscle mass have lower self-reported physical disability, are more likely to use assistive devices, and have more falls.
11 Physical function is important for patients to maintain independence in their activities of daily living, and it correlates with overall quality of life. 12 The cause of cachexia is not entirely clear, but inflammatory cytokines are thought to play an important role. 13 Despite efforts to prevent and treat sarcopenia, no treatment has been successful to date. Long-term side effects accompany current therapies such as megestrol and dexamethasone.
14 Melatonin, eicosapentaenoic acid diester, cannabis, and d-9-tetrahydrocannabinol have not demonstrated significant benefit compared with placebo. 5 Anabolic steroids increase muscle mass, but systemic androgenic side effects limit their use clinically. 15 Two large clinical trials recently evaluated potential medications for the treatment of cachexia, enobosarm, and anamorelin. 16, 17 These trials showed some clinical effect, but they have not led to U.S. Food and Drug Administration approval of the tested drugs.
Identifying at-risk patients would be helpful for designing future clinical trials and guiding treatment efforts. Targeting patients who are at risk for development of muscle wasting or functional decline may lead to more successful interventions. The aim of this study was to determine which patient factors are associated with loss of muscle mass and which patient factors are associated with decline in muscle function in patients with lung cancer who are starting to undergo chemotherapy.
Materials and Methods

POWER Trials
We performed a secondary analysis of the control arm of two phase 3 trials to determine which baseline characteristics predicted loss of lean body mass (LBM) or decline in stair climb power (SCP). The Prevention and treatment Of muscle Wasting in patients with cancER (POWER) trials were two identically designed, randomized, double-blind, placebo-controlled, multicenter, and multinational phase 3 trials that enrolled patients with advanced-stage NSCLC who were starting to undergo first-line chemotherapy. The purpose of these two trials was to evaluate the safety and efficacy of a selective androgen receptor modulator (enobosarm) on the prevention and treatment of muscle wasting. 17 The chemotherapy regimens included a platinumbased chemotherapy agent and either a taxane (POWER 1) or a nontaxane (POWER 2) chemotherapy agent. Baseline characteristics at randomization included demographic and health information, as well as baseline dual-energy X-ray absorptiometry (DXA) to measure LBM before starting chemotherapy. The patients in the intervention arm received the study drug, enobosarm, as well as their scheduled chemotherapy. The patients in the placebo arm received their scheduled chemotherapy without the study drug. The coprimary end points were assessed at day 84 of therapy and included LBM (as measured by DXA) and a functional assessment (as measured by SCP). Durability of response was assessed at day 147 as well, which was also the end of the intervention period with the study drug. Computed tomography scans were performed at baseline, day 84, and day 147 to assess tumor status.
We performed a secondary analysis of the control arm to assess the changes in LBM and muscle function in patients with lung cancer who were receiving chemotherapy. Our goal was to identify which patient characteristics predicted a loss of LBM or a decline in SCP in the patients on the control arm. Our focus on the placebo group was to avoid confounding effects of the experimental drug. The primary intervention in the patients whom we analyzed was initiation of first-line chemotherapy. We used the same end points as the original trials, which were LBM and SCP at day 84 of treatment.
Patients
A total of 321 patients were enrolled into POWER 1 and 320 patients were enrolled in POWER 2; they patients were from 60 participating academic and experienced community sites in the United States, Argentina, Peru, Chile, Hungary, Poland, Russia, and Ukraine (Fig. 1 ). Patients were enrolled from 2011 to 2013. All the patients had received a diagnosis of stage III or stage IV NSCLC, and they were planning to undergo first-line chemotherapy with either a platinum and a taxane or a platinum and a nontaxane. To be eligible for the trials, patients had to have a life expectancy of more than 6 months and an Eastern Cooperative Oncology Group (EOCG) performance status of 0 or 1. Baseline DXA scan, SCP assessment, and laboratory data were collected before the initiation of chemotherapy. Voluntary signed informed consent was obtained before entry into the study. The independent ethics committee and institutional review board gave a favorable opinion of the study.
The inclusion criteria included age of at least 30 years. Females had to be postmenopausal and males had to meet a prostate-specific antigen cutoff or have a negative prostate biopsy result. BMI could not exceed 32, and body weight could not exceed 300 pounds (136 kg). Serum creatinine levels had to be less than or equal to 2.0 mg/dL. Exclusion criteria included having a clinically significant concurrent illness that would preclude compliance or follow-up, stage 4 chronic obstructive pulmonary disease, uncontrolled hypertension, congestive heart failure, or angina. Laboratory exclusion criteria included aspartate transaminase or alanine transaminase level more than 1.5 times the upper limit of normal, alkaline phosphatase level more than three times the upper limit of normal, or bilirubin level more than 2 mg/dL. Patients with a positive screen for human immunodeficiency virus, hepatitis A, hepatitis B, or hepatitis C were excluded. Patients were excluded if they were taking testosterone or androgen agents, megestrol acetate, dronabinol, or any other prescription medication intended to treat weight loss. Patients with active cancer other than NSCLC within the prior 2 years were excluded. In addition, the patients with a very poor baseline stair climb time (>30 seconds) were also excluded.
Body Composition
A weight history over the prior 6 months was obtained from each patient at screening. Body weight was assessed at baseline and every 21 days for a total of 147 days. Weight loss was calculated as the difference between body weight at baseline and at 6 months before enrollment and expressed as a percentage. Height was assessed at baseline. Whole body DXA was performed at day 0, day 42, day 84, and day 147. DXA was chosen as the method to assess LBM because of its reliability, availability, and accuracy. 18 The change in LBM was expressed as a percentage and calculated as the difference between LBM at baseline and at day 84 of treatment.
Physical Functioning
The SCP test is a clinically meaningful test of muscle function that is associated with strength, balance, and overall mobility. 19 SCP was calculated by using the formula Power (watts) ¼ Force Â Velocity, with use of the patient's weight, the height of the stairs climbed, and the amount of time taken to ascend. Change in SCP was expressed as a percentage that was calculated as the difference between SCP at baseline and at day 84 of treatment.
Data Analysis
The baseline characteristics that were dichotomous variables included stage (III or IV), sex, ECOG performance status (0 or 1), taxane use (yes or no), presence of comorbidities (yes or no), weight loss (!5% or <5%), and age (<65 years old or >65 years old). The categorical baseline variables included smoking status (never, current, or prior) and tumor response at day 84 of therapy (partial response, complete response, progressive disease, or not evaluable). The baseline characteristics that were continuous variables included baseline BMI, baseline LBM, and baseline SCP.
The percent change in SCP at day 84 relative to baseline was computed and recoded into an ordinal variable with four levels: at least a 10% increase, a 0% to 10% increase, a 0% to 10% decrease, and more than a 10% decrease. Similarly, the percent change in LBM at day 84 relative to baseline was recoded into an original variable with four levels: more than a 5% increase, a 0% to 5% increase, a 0% to 5% decrease, and more than a 5% decrease. Cumulative logit models were used to investigate the association between the risk factors on the basis of baseline patient characteristics and the ordinal outcomes. The analysis focused on the effect of these risk factors on the OR of having higher-level loss of SCP and LBM loss relative to having lower-level loss. The patients on the control arm from the two trials were pooled for the analysis. The clinically relevant available risk factors were identified. Potential risk factors eligible for model selection were age, sex (male versus female), ECOG PS (0 versus 1), weight loss in the prior 6 months (>5% versus 5%), BMI, baseline SCP and LBM, tumor response by day 84 (complete or partial response, stable, progressed, or other), comorbidity (yes versus no), and use of taxane (yes versus no). The proportional odds (PO) assumption was tested for each cumulative logit model. 20 All p values were two sided and not adjusted for multiplicity. Given the small proportion of patients with missing outcome or baseline covariates, complete case analysis was used for handling missing data. All statistical analyses were done with SAS software (version 9.4, SAS Institute Inc., Cary, NC).
Results
Patients
In the POWER trials, a total of 322 patients were randomized to placebo. After excluding patients who had died by day 84 of treatment, those missing outcome data at day 84 of treatment, and those missing covariates, we analyzed data from 232 patients for the LBM end point and data from 236 patients for the SCP end point (see Fig. 1 ). The study population had the age, sex, and comorbidities expected of patients with advanced lung cancer. Despite needing to have a good performance status to be eligible for enrollment, 50% of patients had lost at least 5% of their body weight in the prior 6 months. At baseline, there was a wide range of values for BMI, LBM, and SCP. The baseline patient characteristics that we analyzed can be found in Table 1 . Tumor response was assessed at day 84 of treatment. A total of 97 patients (30.1%) had a partial or complete response, 129 (40.1%) had stable disease, and 96 (29.8%) had progressive disease or were not evaluable.
Outcome Variables
The two outcome variables that we looked at were change in LBM and change in SCP. The change in LBM was calculated as a percentage change from baseline (day 0) to day 84 of treatment. At day 84 of treatment, 53% of patients who were receiving chemotherapy had seen a decline in their LBM. In all, 50 patients (21%) had lost at least 5% of their LBM. We analyzed the outcomes as ordinal variables with four levels: more than a 5% gain, a 0% to 5% gain, a 0% to 5% loss, and more than a 5% loss. These levels were chosen on the basis of the distribution of values and because a value of 5% parallels the 5% weight loss present in the definition of cachexia. 1 The details of change in LBM in our patient population can be found in Table 2 .
The change in SCP was calculated as the percentage change from baseline (day 0) to day 84 of treatment. Almost half (49%) of the patients had a decline in their SCP from baseline to day 84 of treatment, and 79 (31%) had at least a 10% decline in their SCP. The 10% increase between levels was justified on the basis of prior studies that have demonstrated a change of more than 10% to be a "substantial meaningful" change. 21, 22 The details of change in SCP in our patient population can be found in Table 2 .
Body Composition Results
Patients who received taxane chemotherapy or those with an ECOG performance status of 1 trended toward losing more LBM than their counterparts. Patients with better tumor response at day 84 of treatment trended toward losing less LBM than those with progressive disease, but these results did not reach statistical significance. Stage was the only significant predictor of loss of LBM. Patients with stage 4 disease were more likely than those with stage 3 disease to have a loss of LBM over the course of treatment. The full results for LBM can be found in Table 3 .
Physical Function Results
The PO assumption was tested for the cumulative logit model for functional decline; the p value was 0.042, which suggests a moderate violation. It is well known in statistical literature that the test for the PO assumption tends to be too liberal, and the assumption is overtly rejected, especially when the sample size is small or moderate. 20 Plots for the regression coefficients of cumulative logit models, which allow separate sets of effects for separate logits, revealed that the violation is moderate and quantitative for all predictors except for Patients who stopped smoking more than 1 year before enrollment had more SCP decline than did the patients who were still smoking within the year. Patients with a higher SCP at baseline were more likely to lose at least 10% of their SCP. Similar to the results for LBM, patients with a higher ECOG performance status at baseline were more likely to have SCP decline, but the difference was not statistically significant. Patients with a higher BMI at baseline were less likely to lose SCP. Patients with higher LBM at baseline were also less likely to lose SCP, but the difference was not statistically significant. The full results for SCP can be found in Table 3 .
As expected, we showed a relationship between change in LBM and weight change with an R 2 value of 0.34. By contrast, although there was some relationship between body composition as measured by LBM and functional loss as measured by SCP, the association was limited, as is illustrated in Figure 2 . The R 2 of this relationship was 0.096. Although both are related to the cachexia syndrome, they are two distinct entities.
Discussion
This study was a secondary analysis of two randomized controlled trials that were performed to evaluate the effect of a study drug on the prevention and treatment of muscle wasting in patients with lung cancer who were starting to undergo chemotherapy. The aim of our study was to identify predictors of loss of LBM or decline in SCP in patients receiving chemotherapy. We looked at the control group, whose members did not get the study drug but did get first-line chemotherapy. We wanted to identify at-risk patients, as these patients could be targeted for interventions in the future. At day 84 of treatment, approximately 50% of patients had lost LBM and approximately 50% of patients had a decline in their SCP. This high prevalence of depletion of muscle mass and decline in strength is consistent with previous accounts of sarcopenia in patients with NSCLC. At referral to oncologists, up to 47% of patients with NSCLC already have severe muscle depletion. 23 We found that patients with stage 4 disease were more likely to have a decline in LBM throughout the course of treatment. Stage as a significant predictor suggested that patients with more advanced disease were more likely to lose LBM. Despite the association between muscle depletion and mortality in patients with cancer, 3, 9 previous cross-sectional studies have not found stage to be associated with sarcopenia. 4, 24 In this study, patients with a higher ECOG performance status and patients who were 65 years or older trended toward losing more SCP; however, the differences were not statistically significant.
Myalgia and neuropathy are common side effects of taxane chemotherapy, and it has been proposed previously that taxanes may impair physical function. 25, 26 Steroids are often given to prevent or treat myalgia in patients receiving taxane therapy, and glucocorticoid use is known to play a part in muscle catabolism. 27 In accordance with these observations, the patients in our study who received taxane chemotherapy were more likely to have a decline in their SCP. Similarly, a recent longitudinal study showed a decline in both patientreported and objective measures of physical function in patients receiving taxane chemotherapy. 28 Several studies have suggested that sarcopenia is more prevalent in men than in women. 4, 23, 29, 30 In this study, we did not find a sex predilection for either loss of LBM or decline in SCP. Many studies have shown an association between increasing age and muscle mass decline 11, 31, 32 In this study, age was not a significant predictor of physical or functional loss. Unlike in most studies on sarcopenia, we used each patient as his or her own control to assess percent change from baseline. Although age and sex may be associated with the presence of sarcopenia, according to the present study they were not a significant predictor of relative decline in muscle mass in this population.
Both observational and longitudinal studies have shown an association between smoking and sarcopenia. 11, 33 Even with control for for physical activity, the relationship between smoking and muscle mass loss and functional decline persisted. 33 A recent meta-analysis concluded that cigarette smoking independently contributes to sarcopenia; however, the authors of the meta-analysis noted that the large heterogeneity among the studies could have affected the results. 34 Interestingly, we found that patients who had quit smoking more than 1 year before starting the study experienced more of a decline in SCP than did patients who continued to smoke. An explanation for this finding is that patients who quit smoking more than 1 year prior may have done so on account of their medical comorbidities and therefore may have been a sicker cohort of patients. When we analyzed the smoking data further, we found that patients who were categorized as "before smokers" were older and also had more medical comorbidities than did patients who continued to smoke. In addition, weight gain is an expected side effect of smoking cessation, and these extra pounds may have contributed to the decline in SCP of patients who had recently quit smoking. Future studies are needed to further investigate the association of smoking cessation and muscle function.
Patients with a higher baseline SCP were more likely to lose more than 10% of their SCP. This finding was thought to be a function of relative change because we used each patient as his or her own reference. Conversely, a higher BMI at baseline was protective against decline in SCP. In a previous study of community-dwelling nonobese women, skeletal muscle mass correlated with both BMI and objective measures of muscle strength. 35 Similarly, a longitudinal study of community-dwelling elderly Japanese women showed that development of sarcopenia was more likely in women with a lower baseline BMI. 36 The fact that BMI is a protective factor is possibly due to the association between LBM and BMI. In our study, baseline LBM trended toward being protective against SCP decline, but this result was not statistically significant.
Compared with the change in LBM, we found many more significant predictors of functional decline. For the variable LBM, we used a loss of at least 5% as our cutoff for comparison. Our use of a threshold value of 5% was in contrast to the original trials, which used maintenance of LBM as the threshold value. Because we chose a higher threshold of LBM loss for our comparison, we may have excluded variables that would have been significant at a lower threshold. LBM is a singular measure of body composition, whereas SCP is a functional measure with many interrelated components, including lower extremity power, balance, agility, and strength. 37 This fundamental difference in the two measurements may also account for some of the discrepancy in the number of significant variables.
As expected, we showed a relationship between LBM change and weight change (see Fig. 2 ). In contrast, although there is some relationship between LBM and SCP, the association is limited, as is illustrated in Figure 3 . Previous studies have shown an association between muscle mass and various subjective and objective measures of functional status, including hand grip strength and the Timed Up and Go test. 4, 35, 36, 38 A recent study used computed tomography scan to measure skeletal muscle density and skeletal muscle index. Although a lower skeletal muscle density correlated with worsening frailty, a patient's overall muscle mass, as measured by skeletal muscle index, was poorly associated with frailty. 39 A longitudinal study that followed 1880 older adults over 3 years found that the relationship between muscle mass and strength is nonlinear and strength declines more rapidly than absolute muscle mass. 29 In our study, we also found that the relationship between LBM and SCP is limited, and further studies should explore the relationship between physical and functional decline. Although both are related to the cachexia syndrome, they are two distinct entities.
The limitations of this study include the exclusion of patients with early-stage disease, patients with poor ECOG performance status, and patients at the extremes of BMI. Excluding these patients may have decreased the sensitivity of our results or made the results less generalizable to the general population. The large amount of dropout due to missing variables may have affected the results, with 59 patients in the LBM group excluded and 55 patients in the SCP group excluded. We believe that rather than this dropout being a random event, the patients who dropped out were likely sicker. Because this study was a secondary analysis of a completed trial, we were unable to test variables that were not recorded by the original investigators. For example, we were interested in looking at baseline inflammatory markers, such as erythrocyte sedimentation rate and C-reactive protein level, but these values were not collected during the study and could not be included in our analysis. The large number of included patients is one of the strengths of this study. Additionally, the longitudinal design of this study allowed us to determine predictors of change in muscle mass and muscle function. We analyzed patients with only one type of cancer, NSCLC, and all of them were receiving platinum-based chemotherapy, which limited sampling bias and decreased heterogeneity.
We have identified predictors of physical and functional loss in patients with lung cancer who were starting to undergo chemotherapy. This was a descriptive study, and additional studies are needed to confirm these predictive factors. In addition, we found a dissociation between SCP decline and LBM loss. Clinical trials should further explore the relationship between physical and functional loss.
